EP1491889A3 - Méthode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x = 41) et de la protéine tau - Google Patents

Méthode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x = 41) et de la protéine tau Download PDF

Info

Publication number
EP1491889A3
EP1491889A3 EP04077711A EP04077711A EP1491889A3 EP 1491889 A3 EP1491889 A3 EP 1491889A3 EP 04077711 A EP04077711 A EP 04077711A EP 04077711 A EP04077711 A EP 04077711A EP 1491889 A3 EP1491889 A3 EP 1491889A3
Authority
EP
European Patent Office
Prior art keywords
alzheimer
disease
tau
diagnosis
aiding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04077711A
Other languages
German (de)
English (en)
Other versions
EP1491889A2 (fr
Inventor
Peter A. Seubert
Carmen Vigo-Pelfrey
Dale B. Schenk
Robin Barbour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1491889(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/339,141 external-priority patent/US6114133A/en
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of EP1491889A2 publication Critical patent/EP1491889A2/fr
Publication of EP1491889A3 publication Critical patent/EP1491889A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP04077711A 1994-11-14 1995-11-13 Méthode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x = 41) et de la protéine tau Withdrawn EP1491889A3 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/339,141 US6114133A (en) 1994-11-14 1994-11-14 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US41900895A 1995-04-07 1995-04-07
US419008 1995-04-07
EP95939892A EP0792458B1 (fr) 1994-11-14 1995-11-13 Methode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x- 41) et de la proteine tau
US339141 1999-09-24

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP95939892A Division EP0792458B1 (fr) 1994-11-14 1995-11-13 Methode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x- 41) et de la proteine tau
EP95939892.6 Division 1995-11-13

Publications (2)

Publication Number Publication Date
EP1491889A2 EP1491889A2 (fr) 2004-12-29
EP1491889A3 true EP1491889A3 (fr) 2005-04-06

Family

ID=26991508

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04077711A Withdrawn EP1491889A3 (fr) 1994-11-14 1995-11-13 Méthode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x = 41) et de la protéine tau
EP95939892A Revoked EP0792458B1 (fr) 1994-11-14 1995-11-13 Methode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x- 41) et de la proteine tau

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP95939892A Revoked EP0792458B1 (fr) 1994-11-14 1995-11-13 Methode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x- 41) et de la proteine tau

Country Status (11)

Country Link
US (4) US7427392B1 (fr)
EP (2) EP1491889A3 (fr)
JP (2) JP3634375B2 (fr)
AT (1) ATE278957T1 (fr)
AU (1) AU705907B2 (fr)
CA (1) CA2205359C (fr)
DE (1) DE69533623T2 (fr)
DK (1) DK0792458T3 (fr)
ES (1) ES2230551T3 (fr)
PT (1) PT792458E (fr)
WO (1) WO1996015452A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
BR9913112A (pt) * 1998-09-08 2001-05-08 Innogenetics Nv Tau como um marcador para dano inicial de cns
AU2001268005A1 (en) * 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20070128191A1 (en) * 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006053251A2 (fr) * 2004-11-12 2006-05-18 Pfizer, Inc. Methode permettant de mesurer des peptides beta-amyloides
WO2007044094A1 (fr) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Modifications specifique de la maladie d'alzheimer du rapport de phosphorylation erk1/erk2 utilise comme biomarqueurs moleculaires specifiques de la maladie d'alzheimer (adsmb)
AU2007227813B2 (en) 2006-03-23 2012-09-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
EP1944314A1 (fr) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Diagnostic de la maladie d'Alzheimer et d'autres désordres neurologiques
EP2578692B1 (fr) 2007-04-05 2016-06-08 The J. David Gladstone Institutes Agents qui réduisent la sur-excitation neuronale
EP2009445A1 (fr) * 2007-06-29 2008-12-31 Institut Pasteur Utilisation d'anticorps à domaine simple de chaînes pour détecter une formule oligomérique d'un peptide amyloide bêta et ses applications
EP2020602A1 (fr) * 2007-08-02 2009-02-04 Araclon Biotech Immunoessais à haute sensibilité et kits pour la détermination de peptides et de protéines d'intérêt biologique
CA2753586A1 (fr) * 2009-02-24 2010-09-02 Winton G. Gibbons Detection de complexes formes entre la proteine tau et un amyloide
CN102428101B (zh) * 2009-03-18 2016-03-02 Ac免疫有限公司 用于治疗用途的方法
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP2258398A1 (fr) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Conjugués d'albumine-peptide d'amyloide et leurs utilisations
WO2012142301A2 (fr) 2011-04-12 2012-10-18 Quanterix Corporation Procédé de détermination d'un protocole de traitement et/ou d'un pronostic de rétablissement d'un patient à la suite d'un traumatisme cérébral
PL2579042T3 (pl) * 2011-10-04 2014-12-31 Affiris Ag Sposób wykrywania przeciwciał swoistych wobec Aß w próbce biologicznej
DE102011057021A1 (de) 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
US20150031054A1 (en) 2012-01-27 2015-01-29 Panasonic Healthcare Co., Ltd. Method and system for diagnosing alzheimer's disease
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
PL2885010T3 (pl) 2012-08-16 2020-11-16 Ipierian, Inc. Metody leczenia tauopatii
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2495266B8 (es) 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
SG10201707855YA (en) * 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
WO2014150877A2 (fr) 2013-03-15 2014-09-25 Ac Immune S.A. Anticorps anti-tau et leurs procédés d'utilisation
KR20140128230A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트
WO2015020523A1 (fr) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarqueurs pour diagnostic précoce de la maladie d'alzheimer
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
KR101890978B1 (ko) 2014-06-17 2018-08-24 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
JO3537B1 (ar) 2014-07-10 2020-07-05 Bioarctic Neuroscience Ab أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة
EA201892412A1 (ru) * 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
EP3452508A1 (fr) 2016-05-02 2019-03-13 Prothena Biosciences Limited Anticorps reconnaissant tau
EP3452507B1 (fr) 2016-05-02 2022-10-19 Prothena Biosciences Limited Immunothérapie anti-tau
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
KR20200077543A (ko) 2017-10-25 2020-06-30 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
EP3881229A1 (fr) 2018-11-14 2021-09-22 Qynapse Procede de determination d'un modele de prediction, procede de prediction de l'evolution d'un k-uplet de marqueurs mk et dispositif associe
WO2020163730A2 (fr) 2019-02-08 2020-08-13 Ac Immune S.A. Méthode d'administration sûre d'un vaccin de peptide de tau phosphorylé
WO2020180819A1 (fr) 2019-03-03 2020-09-10 Prothena Biosciences Limited Anticorps reconnaissant la protéine tau
EP3965817A4 (fr) 2019-04-24 2023-11-22 Janssen Pharmaceuticals, Inc. Administration hétérologue de vaccins tau

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444856A2 (fr) * 1990-02-26 1991-09-04 Albert Einstein College Of Medicine Of Yeshiva University Procédé pour la détection de la maladie d'Alzheimer
WO1994010569A1 (fr) * 1992-10-26 1994-05-11 Schenk Dale B PROCEDES ET COMPOSITIONS VISANT A DETECTER UN PEPTIDE β-AMYLOIDE SOLUBLE

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271140A (en) 1978-01-23 1981-06-02 Baxter Travenol Laboratories, Inc. Method and composition for double receptor, specific binding assays
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS6267297A (ja) 1985-09-18 1987-03-26 Hitachi Ltd ポンプの軸受潤滑装置
ATE169673T1 (de) 1986-11-17 1998-08-15 Scios Inc Rekombiniertes alzheimer amyloid-protein
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
AU5439790A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
DE69133372T2 (de) * 1990-06-15 2005-02-24 Scios Inc., Sunnyvale Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
JPH04252955A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
JPH04252956A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US20030086938A1 (en) 2000-02-21 2003-05-08 Jensen Martin Roland Novel methods for down-regulation of amyloid
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US7380724B2 (en) 2002-07-01 2008-06-03 Sony Ericsson Mobile Communications Ab Entering text into an electronic communication device
CN100379696C (zh) 2002-10-29 2008-04-09 Hoya株式会社 化学强化玻璃、信息记录介质用基板及信息记录介质
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444856A2 (fr) * 1990-02-26 1991-09-04 Albert Einstein College Of Medicine Of Yeshiva University Procédé pour la détection de la maladie d'Alzheimer
WO1994010569A1 (fr) * 1992-10-26 1994-05-11 Schenk Dale B PROCEDES ET COMPOSITIONS VISANT A DETECTER UN PEPTIDE β-AMYLOIDE SOLUBLE

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHUI ET AL.: "Reliability and usefulness of a new immunochemical assay for Alzheimer's disease", ARCH. NEUROL., vol. 50, January 1993 (1993-01-01), pages 57 - 63, XP008042722 *
HAASS C ET AL: "AMYLOID BETA-PEPTIDE IS PRODUCED BY CULTURED CELLS DURING NORMAL METABOLISM", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 359, no. 6393, 24 September 1992 (1992-09-24), pages 322 - 325, XP000616172, ISSN: 0028-0836 *
IWATSUBO ET AL.: "Visualization of Aß42(43) and Aß40 in senile plaques with end-specific AB monoclonals: Evidence that an initially deposited species is Aß42(43)", NEURON, vol. 13, July 1994 (1994-07-01), pages 45 - 53, XP002089557 *
SEUBERT P ET AL: "ISOLATION AND QUANTIFICATION OF SOLUBLE ALZHEIMER'S BETA-PEPTIDE FROM BIOLOGICAL FLUIDS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 359, no. 6393, 24 September 1992 (1992-09-24), pages 325 - 327, XP000616173, ISSN: 0028-0836 *
UÉDA K ET AL: "ALZ-50 RECOGNIZES A PHOSPHORYLATED EPITOPE OF TAU PROTEIN", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 10, no. 10, 1 October 1990 (1990-10-01), pages 3295 - 3304, XP000600531, ISSN: 0270-6474 *
VANDERMEEREN M ET AL: "DETECTION OF TAU PROTEINS IN NORMAL AND ALZHEIMER'S DISEASE CEREBROSPINAL FLUID WITH A SENSITIVE SANDWICH ENZYME-LINKED IMMUNOSORBENT ASSAY", JOURNAL OF NEUROBIOLOGY, JOHN WILEY AND SONS., NEW YORK, NY, US, vol. 61, no. 5, November 1993 (1993-11-01), pages 1828 - 1834, XP000999832, ISSN: 0022-3034 *
VIGO-PELFREY ET AL.: "Characterization of ß-amyloid peptide from human cerebrospinal fluid", JOURNAL OF NEUROCHEMISTRY, vol. 61, no. 5, November 1993 (1993-11-01), pages 1965 - 1968, XP002089556 *
WOLOZIN ET AL.: "Alzheimer-related neuronal protein A68: Specificity and distribution", ANN. NEUROL., vol. 22, 1987, pages 521 - 526, XP008042723 *

Also Published As

Publication number Publication date
DE69533623T2 (de) 2006-03-02
EP1491889A2 (fr) 2004-12-29
US7700309B2 (en) 2010-04-20
ATE278957T1 (de) 2004-10-15
ES2230551T3 (es) 2005-05-01
DE69533623D1 (de) 2004-11-11
EP0792458A1 (fr) 1997-09-03
CA2205359A1 (fr) 1996-05-23
US20040253643A1 (en) 2004-12-16
US7427392B1 (en) 2008-09-23
JPH10509797A (ja) 1998-09-22
US20050069968A1 (en) 2005-03-31
EP0792458A4 (fr) 1999-04-07
AU705907B2 (en) 1999-06-03
AU4154496A (en) 1996-06-06
JP3634375B2 (ja) 2005-03-30
PT792458E (pt) 2005-02-28
EP0792458B1 (fr) 2004-10-06
JP2004077499A (ja) 2004-03-11
DK0792458T3 (da) 2005-01-31
US7811769B2 (en) 2010-10-12
US20040265920A1 (en) 2004-12-30
CA2205359C (fr) 2006-07-04
WO1996015452A1 (fr) 1996-05-23

Similar Documents

Publication Publication Date Title
EP1491889A3 (fr) Méthode d'assistance au diagnostic de la maladie d'alzheimer par mesure du peptide amyloide-beta (x = 41) et de la protéine tau
EP0934752A3 (fr) Pompe de perfusion volumétrique
Rau et al. A modified version of Larsen’s scoring method to assess radiologic changes in rheumatoid arthritis
EP1521083A3 (fr) Procédé pour le diagnostic et la caractérisation de l'attaque cérébrale
Field et al. Algodystrophy after Colles fractures is associated with secondary tightness of casts
EP0981048A3 (fr) Détecteur de caillots de sang
EP1798288A3 (fr) Récepteurs protéiques humains du type Toll, réactifs connexés et techniques afférentes
HUP0202889A2 (en) Method and sensor for measuring the concentration of an analyte in an ocular fluid
DK528385A (da) Kontrastmidler
AU2002254029A1 (en) Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
EP1408333A3 (fr) Diagnostic et traitement de la maladie d'Alzheimer
WO2002041842A3 (fr) Anticorps pti-hs7 destine au traitement de la maladie d'alzheimer et d'autres amyloidoses et de la maladie de parkinson
IL135211A0 (en) Diagnostic test for alzheimer's disease
US5732721A (en) Dental floss with a pressure sensitive material
CA2172243A1 (fr) Methode pour l'analyse quantitative des liquides organiques
Waye et al. The Pancreas.
Jones Jr et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-1995. A 75-year-old man with multiple cranial-nerve defects and weakness and pain in the extremities
Osborne et al. Mechanical properties and clinical performance of a gallium restorative material
DE69431051D1 (de) Verfahren zur bestimmung der diabetesanfälligkeit bei asymptomatischen patienten
Petitti et al. Physiologic measures in men with and without vasectomies
WO1992005278A3 (fr) Procede de determination de l'expression differentielle de arn pour la proteine precurseur de l'amyloide
AU2002366555A1 (en) Diagnostic for early stage alzheimer's disease
IE40645B1 (en) Visual method for the detection of syphilis and other treponemal diseases, and an antigen preparation useful therein
WO2006084430A1 (fr) Dispositif pour determiner la force et la trajectoire de corps ou de parties de corps se deplaçant dans un systeme hygieniquement ferme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0792458

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SEUBERT, PETER, A.

Inventor name: BARBOUR, ROBIN

Inventor name: VIGO-PELFREY, CARMEN

Inventor name: SCHENK, DALE, B.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARBOUR, ROBIN

Inventor name: SEUBERT, PETER, A.

Inventor name: VIGO-PELFREY, CARMEN

Inventor name: SCHENK, DALE, B.

17P Request for examination filed

Effective date: 20050915

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20071214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120301